Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

@inproceedings{Bgin2014Phase1R,
  title={Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab},
  author={Philippe B{\'e}gin and Tina L R Dominguez and Shruti P Wilson and Liane R Bacal and Anjuli Mehrotra and Bethany Kausch and Anthony Trela and Morvarid Tavassoli and Elisabeth G Hoyte and Gerri O’Riordan and Alanna Blakemore and Scott M. Seki and Robert M. Hamilton and Kari Christine Nadeau},
  booktitle={Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology},
  year={2014}
}
BACKGROUND Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein. OBJECTIVE To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protocol using omalizumab to allow for a faster and safe desensitization to multiple foods simultaneously… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

Ebo DG: State of the art and perspectives in food allergy (part II): therapy

  • V Sabato, M Faber, +4 authors LS De Clerck
  • Curr Pharm Des
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…